USP33 and neoplasm: Following disease progression on this trial, genomic testing revealed an FGFR2-USP33 fusion, and she subsequently started a basket trial for the FGFR-selective inhibitor pemigatinib where she exhibited a partial response with a 43% reduction in tumor size (NCT02393248) and remained on therapy for 28 months (Fig. 1A, Supplementary Figs. 1, 2B, 4)8.